New Share News | The IPO prospectus of Xinde Technology for Hong Kong stocks has become invalid.

Shandong Xinde Technology Co., Ltd. (abbreviated as Xinde Technology) submitted its Hong Kong stock prospectus on February 16, 2026, which will expire after six months on August 16, 2026. When the application was submitted, ICBC International and Zhongtai International served as its joint sponsors. According to the prospectus, Xinde Technology was established in 1999 and is a leading animal health enterprise in China. The company is primarily engaged in the research and development, production, and sales of a full range of animal health and related products, including veterinary biological products (such as vaccines, antibodies, transfer factors, etc.), traditional Chinese veterinary medicine, chemical preparations, animal feed, and feed additives, achieving prevention, diagnosis, treatment, and control of diseases in poultry, livestock, aquatic animals, and pets. According to data from ZhiShi Consulting, based on 2024 revenue, the company ranks as the ninth largest domestic manufacturer in China's animal health market and among the top three in the market for veterinary biological products for poultry in China.